NCT05633264View on ClinicalTrials.gov

A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

CompletedOBSERVATIONAL
Enrollment

369

Participants

Timeline

Start Date

December 5, 2022

Primary Completion Date

May 28, 2025

Study Completion Date

May 28, 2025

Conditions
Psoriasis
Trial Locations (1)

171-0021

EP Pharmaline, Tosima-ku

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05633264 - A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan | Biotech Hunter | Biotech Hunter